Iambic Therapeutics closed an oversubscribed financing of over $100 million to accelerate its AI‑discovered therapeutic pipeline and platform development. The round drew strategic and institutional investors, including venture and biopharma backers, and follows recent early‑stage clinical data from Iambic’s HER2‑targeted programs. Company filings and press releases frame the raise as growth capital for multiple IND‑enabling programs and further discovery collaborations.